Table 1

Clinical histories of patients with CPI-induced insulin-dependent diabetes

PatientAge, yearsSexType of cancerCPICycles of treatment at diagnosis, nOther therapiesOther CPI irAERelevant PMH
157FMelanomaI, N, I/N3NoneThyroiditis, hypothyroidism, hypopituitarism, hepatitisNC
261MMelanomaI/N3NoneHypopituitarism, nephritisNC
355FOcular melanomaI/N, I2NoneThyroiditis, hypothyroidism, pancreatitisHashimoto thyroiditis
464FMelanomaP5NoneHypothyroidism, pancreatitis, hepatitis, arthritisHashimoto thyroiditis
580FNSCLCN20Carboplatin, gemcitabineNoneSarcoidosis
667MRCCN10Axitinib, sunitinibNoneHypercalcemia
764FMelanomaI/N1NoneThyroiditis, hypothyroidism, hepatitisNC
863MRCCN78IL-2, bevacizumab, IFNHypothyroidismNC
967MGI adenocarcinomaI/N, N6Irinotecan, docetaxelHepatitis, pancreatitisNC
1083MMelanomaI, P11NoneNonePrediabetes
1163FRCCAtezo1IL-2, IFNHypothyroidism, pancreatitisNC
1264FOcular melanomaI, P16ImatinibHypothyroidism, vitiligo, colitisNC
1364MNSCLCI/N1NoneThyroiditis, pancreatitisNC
1483FNSCLCN3NoneNoneNC
1549MPancreatic cancer (Lynch syndrome)P24NoneColitis, pancreatitisVitamin D deficiency
1668FMelanomaI/N2Fluorouracil, leucovorin, irinotecan, oxaliplatinHypothyroidism, pneumonitisHashimoto thyroiditis
1764MMelanomaP, I/N, N12NoneNoneNC
1853MMelanomaP, I/N, N3NoneHypothyroidism, hypophysitis, hepatitis, vitiligoPrediabetes, hypothyroidism
1987FOcular melanomaP8NoneNonePrediabetes, hypothyroidism
2062MNeuroendocrine tumor of the colon (Lynch syndrome)20Carboplatin, etoposideThyroiditis, myocarditis, hepatitis, arthritisPrediabetes, hypothyroidism
2170MSCC (tongue)P12NonePolyarthralgia, pneumonitisHypothyroidism
2264MCholangiocarcinomaP, GM-CSF4Gemcitabine, cisplatinMyasthenia gravisHypothyroidism
2360MMelanomaN, epacadostat10NoneNoneNC
2460MMelanomaI/N, N12NoneColitisNC
2579MMelanomaP2NoneNeurotoxicityNC
2658MSCLCN1Carboplatin, etoposide, paclitaxelLimbic encephalitisType 2 diabetes, lung adenocarcinoma
2780MNSCLCN14Carboplatin-pemetrexed, pemetrexed maintenanceNoneType 2 diabetes, toxic MNG
  • Atezo, atezolizumab; GI, gastrointestinal; GM-CSF, granulocyte-macrophage colony-stimulating factor; I, ipilimumab; INF, interferon; Lynch syndrome, hereditary nonpolyposis colorectal cancer; MNG, multinodular goiter; N, nivolumab; NC, noncontributory; NSCLC, non–small-cell lung cancer; P, pembrolizumab; PMH, past medical history; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer.